FDA favors Novartis medicate for a difficult to-treat sort of lung malignancy Kumar Jeetendra | May 7, 2020 Novartis AG on Wednesday got the U.S. Nourishment and Drug Administration’s endorsement for its medication to get patients with an extreme treat type of lung malignant growth, the drugmaker said. The medication, Tabrecta, has been endorsed to treat patients with a MET exon14 skipping-changed non-little cell lung malignant growth that has spread to different pieces …
